An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

May 31, 2013

Study Completion Date

December 31, 2015

Conditions
Carcinoid Syndrome
Interventions
DRUG

Lanreotide

deep s.c. injection, 120 mg, every 4 weeks (±3 days).

DRUG

Placebo

deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).

Trial Locations (54)

1002

Paul Stradins Clinical University Hospital, Riga

7570

GVI Oncology Clinical Trial Unit, Port Elizabeth

7700

Rondebosch Oncology Unit, Cape Town

11000

Clinic of Endocrinology, diabetes and metabolic diseases, Clinical Center of Serbia, Belgrade

12808

VFN Onkologicka klinika, Prague

15213

UPMC Liver Cancer Center, Pittsburgh

17033

Penn State Milton S. Hershey Medical Center, Hershey

19104

University of Pennsylvania, Philadelphia

23510

Eastern Virginia Medical School, Norfolk

38039

Erciyes University Medical Faculty, Kayseri

39216

University of Mississippi Medical Center, Jackson

40202

Kentuckiana Cancer Institute, Louisville

48109

University of Michigan, Ann Arbor

53226

Froedtert & Medical College of Wisconsin, Milwaukee

58013

Chernivtsi Regional Oncology Center, Chernivtsi

65117

Odessa Regional Clinical Hospital, Odesa

70065

Louisiana State University Health Science Center, Kenner

90048

Cedars Sinai Outpatient Cancer Center, West Hollywood

90073

VA Greater Los Angeles Health Care System, Los Angeles

90095

David Geffen School of Medicine at UCLA, Los Angeles

94305

Stanford Cancer Center, Stanford

97213

Providence Portland Medical Center, Portland

97239

University of New Mexico Cancer Care Center, Albuquerque

Oregon Health Science University, Portland

302015

Santokaba Durlabhji Memorial Hospital and Research Institute, Jaipur

422005

Shatabdi Super Speciality hospital, Mumbai

Unknown

Biocancer - Centro de Pesquisa e Tratamento do Câncer, Belo Horizonte

Hospital LifeCenter, Belo Horizonte

Oxion Medicina Oncológica, Belo Horizonte

Hospital Universitário de Brasilia, Brasília

Hospital Erasto Gaertner, Curitiba

Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre

Hospital de Base de São José do Rio Preto, São José do Rio Preto

Sir Gangaram Hospital, Delhi

Indo-American Cancer Institute & Research Centre, Hyderabad

Omega Hospitals, Hyderabad

Bhagwan Mahaveer cancer hospital and research centre, Jaipur

Tata Memorial Hospital, Mumbai

"Non-Federal Institution of Healthcare Central Clinical Hospital # 1 of the LLC Russian Railways (RZD)", Moscow

"Russian Academy of Medical Sciences Russian Oncological Research Centre named after N.N. Blokhin RAMS", Moscow

"Federal Institution of Healthcare Leningradsky Regional Oncological Dispensary", Saint Petersburg

Groote Schuur Hospital, Cape Town

Westridge Medical Centre, Durban

Cherkassy Regional Oncology Dispensary, Cherkassy

Oncology and Medical Radiology Chair of Dnepropetrovsk State Medical Academy, Dnipro

Regional Anticancer Center, Department of oncoproctology, Donetsk

Municipal Clinical Hospital #2, Proctology department, Kharkiv

Kyiv City Oncological Hospital, Thoracic department, Kyiv

"Medical Centre Mriya", Kyiv

National Cancer Institute, Kyiv

Uzhgorods'ka Tsentral'na Mis'ka Klinichna Likarnya, Mis'kyy Onkologichnyy Tsentr, Uzhhorod

Vinnytsya Regional Clinical Oncological Center, Vinnytsya State Medical University, Vinnytsia

50-367

Klinika Endokrynologii, Diabetologii i Leczenia Izotopami, Wroclaw

21 204

Oncology Institute of Vojvodina, Sremska Kamenica, Kamenitz

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY